Posted by Michael Wonder on 02 Apr 2023
Mitsubishi Tanabe Pharma Canada receives engagement letter from Pan-Canadian Pharmaceutical Alliance for Radicava oral suspension
31 March 2023 - Mitsubishi Tanabe Pharma Canada is pleased to announce the company has entered into negotiations with the pan-Canadian Pharmaceutical Alliance for Radicava oral suspension (edaravone) for the treatment of patients with amyotrophic lateral sclerosis.
Radicava oral suspension has received positive recommendations from the CADTH Canadian Drug Expert Committee and the Institut national d'excellence en santé et en services sociaux (INESSS) for the treatment of patients with amyotrophic lateral sclerosis
